surmount-1 tirzepatide trial obesity without diabetes SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide on ingestive behavior in

15 mg-2: -1.8% [0.19])

Special precautions and warnings for use There are few contraindications for tirzepatide use

Tirzepatide, a novel medical intervention, has been gaining attention for its significant impact on body weight

The prolonged half-life allows for once-weekly administration in humans [1]

The subsequent disclosure of tirzepatide's mechanism through preclinical and clinical studies provides compelling data, strongly indicating its pharmacological properties and affirming its effects on glycemic control

It does this by acting on the glucagon-like peptide-1 (GLP-1) receptor, which reduces fat cells and enhances fat breakdown